Polymorphisms of TGFB1 and VEGF genes and survival of patients with gastric cancer by Guan, Xiaoxiang et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Journal of Experimental & Clinical 
Cancer Research
Open Access Research
Polymorphisms of TGFB1 and VEGF genes and survival of patients 
with gastric cancer
Xiaoxiang Guan1, Hui Zhao1, Jiangong Niu1, Dongfeng Tan2, Jaffer A Ajani3 
and Qingyi Wei*1
Address: 1Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA, 2Department of 
Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA and 3Department of Gastrointestinal Medical 
Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Email: Xiaoxiang Guan - Xguan@mdanderson.org; Hui Zhao - huizhao@mdanderson.org; Jiangong Niu - jniu@mdanderson.org; 
Dongfeng Tan - Dtan@mdanderson.org; Jaffer A Ajani - jajani@mdanderson.org; Qingyi Wei* - qwei@mdanderson.org
* Corresponding author    
Abstract
Background: Some TGFB1 and VEGF polymorphisms are believed to be functional. Given that
these genes are involved in tumor growth and progression including angiogenesis, dissemination,
and invasiveness, we hypothesized that these polymorphisms would be associated with survival in
patients with gastric cancer.
Methods: We genotyped TGFB1 -509 C>T, +1869 T>C, and +915 G>C and VEGF -1498T>C, -
634G>C, and +936C>T in 167 patients with gastric cancer. Using the Kaplan and Meier method,
log-rank tests, and Cox proportional hazard models, we evaluated associations among TGFB1 and
VEGF variants with overall, 1-year, and 2-year survival rates.
Results:  Although there were no significant differences in overall survival rates among all
polymorphisms tested, patients with TGFB1+915CG and CC genotypes had a poorer 2-year
survival (adjusted hazard ratio (HR), 3.06; 95% confidence interval (CI), 1.09–8.62; P = 0.034) than
patients with the GG genotype had. In addition, patients heterozygous for VEGF -634CG also had
a poorer 1-year survival (adjusted HR, 2.08; 95% CI, 1.03–4.22; P = 0.042) than patients with the -
634GG genotype.
Conclusion: Our study suggested that TGFB1+915CG/CC and VEGF -634CG genotypes may be
associated with short-term survival in gastric cancer patients. However, larger studies are needed
to verify these findings.
Introduction
In gastric caner, patients with the same clinicopathologic
characteristics and the same treatment regimens may have
different clinical outcomes. Although stage is the best
available clinical measure of tumor aggression and prog-
nosis, there are clearly important differences even within
the same tumor stage [1,2]. Therefore, it would be helpful
to improve the prognostic accuracy by identifying readily
accessible molecular markers that predict some of the var-
iation in clinical outcomes. In recent decades, many stud-
ies have shown that genetic alterations play roles in the
development and progression of gastric cancer [3].
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Among these molecular markers, single nucleotide poly-
morphisms (SNPs) are the most commonly investigated
genetic variation that may contribute to patients' clinical
outcomes [4].
Epidemiologic and clinical investigations have suggested
that both TGF-1 and VEGF may play an important role in
the oncogenesis of the stomach [5,6]. For example, TGFB1
and  VEGF  variants are associated with altered protein
products, which may contribute to variation in individual
susceptibility to cancer and clinical outcomes [4]. Both
TGFB1 and VEGF genes are highly polymorphic, report-
edly having 168 and 140 variants, respectively, but only
few of these variants are within the promoter or coding
regions that may be potentially functional http://
www.ncbi.nlm.nih.gov/SNP/. Of these variants, several
SNPs have been described as important in modulation of
gene functions [7-9] and reportedly involved in the etiol-
ogy of various cancers [10-13].
The TGF-1 pathway is critically involved in tumor devel-
opment and progression. In tumor cell cultures, TGF-1
has anti-proliferative effects and can block tumor progres-
sion in its early stages, whereas it can also accelerates inva-
sion and metastasis in the later stages of tumor
progression [14,15]. One experimental study reported
that TGF-1-mediated activation of the ALK5-Smad 3
pathway is essential for the Shh protein to promote motil-
ity and invasiveness in gastric cancer cells [16]. Mouse
experiments also showed that altered TGF-1 was associ-
ated with the latent TGF-1 binding proteins that can
cause inflammation and tumors [17] and that the dis-
rupted TGF-1 pathway can lead to tumor growth by
increasing the tumor angiogenesis induced by decreased
expression of thrombospondin-1 [18]. In humans, TGF-
1 had a greater sensitivity than carcino-embryonic anti-
gens in tumor cells from gastric cancer patients [16]. Fur-
thermore, both experimental and clinico-pathological
studies have suggested a role for the VEGF family of pro-
teins in metastasis through the lymphatic system and in
clinical outcomes in several human solid tumors, includ-
ing gastric cancer [19].
In this study, we chose to genotype selected common (i.e.,
minor allele frequency > 0.05) TGFB1 and VEGF SNPs
that either lead to non-synonymous amino acid changes
[20] or have been associated with lower expression levels
of these genes [8,21], which imply these SNPs may be
functional. We hypothesized that potentially functional
polymorphisms in TGFB1 and VEGF would be associated
with clinical outcomes in patients with gastric cancer. Specifi-
cally, we evaluated the association between clinical out-
comes in gastric cancer, including overall survival, and
each of the following SNPs: three TGFB1 SNPs, including
one promoter SNP (-509 C>T) and two exon 1 SNPs
(+869 T>C and +915 G>C) and three VEGF SNPs, includ-
ing one promoter SNP (-1498T>C), one 5'-untranslated
region SNP (-634G>C) and one 3'-untranslated region
SNP (+936 C>T).
Methods
Study population
This prospective analysis consisted of 167 patients with
newly diagnosed and histologically confirmed gastric can-
cer, who were treated at The University of Texas M.D.
Anderson Cancer Center, Houston, Texas between April
2003 and July 2008. The study protocol was approved by
our Institutional Review Board (IRB) and all patients gave
informed consent using the IRB-approved informed con-
sent form. Exclusion criteria included those not newly
diagnosed and those having been treated elsewhere before
coming to M. D. Anderson. These patients were included
in this analysis because their stored blood samples were
available for DNA extraction.
Genotyping
Genomic DNA was extracted from the buffy coat fraction
of the blood sample of each patient by using a Blood Mini
Kit (Qiagen, Valencia, CA) according to the manufac-
turer's instructions. DNA purity and concentrations were
determined by spectrophotometric measurement of
absorbance at 260 and 280 nm by UV spectrophotometer.
The three selected TGFB1  SNPs [one (-509 C>T/
rs1800469) in the promoter and two (+869 T>C/
rs1800470 and +915 G>C/rs1800471) in exon 1] and
three promoter VEGF SNPs [one (-1498T>C/rs833061) in
the promoter, one (-634G>C/rs2010963) in the 5'-
untranslated region, and one (+936C>T/rs3025039) in
the 3'-untranslated region] were genotyped using
polymerase chain reaction(PCR) – restriction fragment
length polymorphism (RFLP) method. Genotypes of the
TGFB1  SNPs were determined as previously
described[22], and assays on the VEGF SNPs were also
previously reported [23]. For the PCR-RFLP-based geno-
typing assay, two research assistants independently read
the gel pictures, and the repeated assays were performed,
if they did not agree on the tested genotype. In addition,
repeated assays were performed on a randomly selected
10% of the samples were randomly selected to perform
the repeated assays with the results being 100% concord-
ant.
Outcome data collection
All 167 gastric cancer patients had available follow-up
data on outcome. The overall survival time was calculated
from the date of registration at M.D. Anderson to the date
of last contact or death. Patients who were still alive at the
last contact were considered as a censored event in the
analysis. The age at diagnosis, sex, and type of treatments
(i.e., surgery and chemotherapy) were used as covariatesJournal of Experimental & Clinical Cancer Research 2009, 28:94 http://www.jeccr.com/content/28/1/94
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in the analysis. The age at diagnosis was categorized into
two groups according to the mean age ( 57 and >57
years).
Statistical Analysis
Two-sided chi-square and t tests were performed to deter-
mine any statistically significant differences in the distri-
butions of categorical variables (e.g., the TGFB1 and VEGF
alleles and genotypes) by demographic variables and clin-
ical features and in the means of continuous variables
(e.g., age and survival time), respectively. The distribu-
tions of the genotypes were tested for deviation from
Hardy-Weinberg equilibrium (HWE), and the haplotypes
for the variants of the same gene were reconstructed
according to the PHASE program [9], by which each indi-
vidual's probability of having a particular haplotype pair
was estimated, and the haplotype pair with the highest
estimated probability was assigned to the individual.
Pearson's chi-square or global test was used to test for the
survival differences among patients by all haplotypes.
Overall survivals among the three genotype groups of
each SNP were analyzed using the Kaplan-Meier method,
and the log-rank test was used to test for the equality of
the survival distributions stratified by genotypes. We used
univariate and multivariate Cox proportional hazards
models to estimate the effect of each genotype on survival
in the presence of other covariates. Both age at diagnosis
and the time interval between registration and diagnosis
date (pathologic confirmation of disease) were treated as
numeric covariates in the Cox model. To confirm the
assumption of proportional hazards in a Cox regression
model, we added a time-dependent variable to the model,
and the assumption was confirmed. Hazard ratios (HRs)
and their corresponding 95% confidence intervals (CIs)
were calculated with adjustment for other covariates in
the same model. The joint effects of the TGFB1 and VEGF
SNPs and their interactions with smoking and drinking
on gastric cancer risk were also evaluated. All statistical
tests were 2-sided, with a P value of 0.05 considered sig-
nificant and all were calculated using SAS software (ver-
sion 9.1; SAS Institute, Cary, NC).
Results
Characteristics of the study population
Clinical and pathological characteristics of the 167
patients enrolled in this study are shown in Table 1. There
were 114 males (68.3%) and 53 females (31.7%), whose
ages ranged from 32 to 89 years. Using the Cox regression
analysis of the relationship between overall survival and
clinicopathologic characteristics, we found that neither
age, gender, ethnicity, smoking, nor alcohol status were
statistically associated with overall survival (P = 0.339,
0.988, 0.297, 0.475, 0.809, respectively).
The tumors of 118 (70.7%) the patients were located at
the stomach and those of 49 (29.3%) patients were
located at the gastroesophageal junction (GEJ). Regardless
of tumor location, all the patients had adenocarcinoma.
Of these, 118 (70.7%) patients were intestinal and 49
(29.3%) signet ring. We grouped the types of differentia-
tion into the following three categories: poor, moderate-
poor and moderate-well, and the number and percentage
of these three groups were 96 (57.8%), 28 (16.9%) and 42
(25.3%), respectively. In all patients, clinico-pathological
characteristics including tumor location, histology and
differentiation status were not significantly associated
with overall survival in the univariate analysis (P = 0.069,
0.356, and 0.694, respectively). Clinical tumor stages
according to the International Union Against Cancer
(UICC) criteria were as follows: 65 (38.9%) had stage I+II
and 101 (61.1) had stage III +IV (Table 1).
Among the 167 patients, 121 (72.4%) received chemo-
therapy, and 63 (37.7%) received surgery; at the end of
the follow-up period, 60 (35.9%) patients had died. The
mean follow-up time was 18.0 ± 13.3 months for the
patients who were still alive, and the mean survival time
for all patients was 29.4 months. Advanced stage, metas-
tasis, chemotherapy and surgery were all associated with
overall survival (P < 0.001 for all) (Table 1). For example,
the mean survival time was 34.2 months for patients with-
out metastasis and 21.2 months for those with metastasis.
Those who received chemotherapy and surgery had a
longer mean survival time than those who did not (26.3
months versus 10.4 months for chemotherapy and 39.2
months versus 18.4 months for surgery).
HWE, linkage disequilibrium and haplotypes TGFB1 and 
VEGF
For  TGFB1, one of the three SNPs (rs1800469C>T,
rs1800470T>C and rs1800471G>C) was not in HWE (P <
0.05 for rs1800469C>T), suggesting a possible selection
bias, but none of the VEGF  SNPs (rs833061T>C,
rs2010963G>C and rs3025039C>T) departed from HWE
(P > 0.05 for all). None of the pairs of TGFB1 or VEGF
SNPs were in high linkage disequilibrium (i.e., r2 between
0.039 and 0.541, all <0.08). Only four TGFB1 haplotypes
and five VEGF haplotypes had an allele frequency of >0.05
(C-T-G, 0.570; C-C-G, 0.190; T-C-G, 0.167 and C-C-C,
0.063 for TGFB1 and C-G-C, 0.344; T-C-C, 0.287; T-G-C,
0.192; C-G-T, 0.072 and T-C-T, 0.051 for VEGF). Because
of the small sample size, we did not calculate the diplo-
types.
TGFB1 and VEGF genotype distributions and overall 
survival
When all gastric cancer patients were analyzed for overall
survival, no significant difference was found in the distri-
butions of mean survival time by genotypes for any of theJournal of Experimental & Clinical Cancer Research 2009, 28:94 http://www.jeccr.com/content/28/1/94
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polymorphisms studied. Because there were few partici-
pants in the minor homozygous variant groups, we com-
bined the heterozygous and minor variant homozygous
genotypes together for additional analysis, assuming a
dominant genetic model, but there was still no associa-
tion between detected polymorphisms and overall sur-
vival (see Additional file 1). Furthermore, when the gastric
cancer patients were stratified by age, sex, ethnicity, and
metastatic status, no difference in the distribution accord-
ing to mean survival time by the six SNPs was found
among the subgroups (see Additional file 1).
TGFB1 and VEGF genotype distributions and 1-and 2-year 
survivals
Because the prognosis is generally poor in advanced cases
of gastric cancer, median survival rarely approaches 1 or 2
years [2]. In the present study, most of the cases were stage
IV (101/167) with a median survival time of only 16.2
months (95% CI, 12.8–24.9). Therefore, we also calcu-
lated the 1-year and 2-year survival rates for patients with
different genotypes (see Additional file 2). The overall 1-
year and 2-year survivals for all patients were 51.5% and
22.1%, respectively. Although there were no significant
differences in the survival rates between most genotypes,
patients with TGFB1 +915CG/CC genotypes had better 1-
Table 1: Characteristics of the study population of patients with gastric cancer
Characteristics No. of Patients No. of Deaths MST (months) P*
Total subjects
Age (mean)
167 60 0.339
57 years 68 27 21.2
>57 years 99 33 31.0
Gender 0.988
Male 114 41 23.3
Female 53 19 28.9
Ethnicity 0.297
White 117 45 28.8
Non-White† 50 15 19.1
Smoke 0.475
Never 34 14 20.6
Ever 133 46 30.1
Alcohol 0.809
Never 62 23 23.2
Ever 105 37 29.3
Location 0.069
Stomach 118 36 24.3
Esophagus 25 13 27.2
GEJ 24 11 16.6
Histology 0.356
Intestinal 118 45 28.1
Signet ring 49 15 24.6
Differentiation 0.694
Poor 96 37 21.8
Moderate-poor 28 10 29.8
Moderate-Well 42 13 22.6
Clinical Stage < 0.001
I + II 65 9 30.4
III + IV 101 51 22.7
Metastasis < 0.001
yes 90 49 21.2
no 77 11 34.2
Chemotherapy < 0.001
yes 121 54 26.3
no 46 6 10.4
Surgery < 0.001
yes 63 11 39.2
no 104 49 18.4
Abbreviations: MST, median survival time; GEJ, gastroesophageal junction.
* Chi-square test.
†Included 13 Asians, 16 blacks, 19 Hispanics, and 2 Native Indians.Journal of Experimental & Clinical Cancer Research 2009, 28:94 http://www.jeccr.com/content/28/1/94
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year and 2-year survival than those with the GG genotype
(adjusted HR, 2.13; 95% CI, 0.76–6.01; P = 0.122 and
adjusted HR, 3.06; 95% CI, 1.09–8.62; P = 0.034, respec-
tively) (Figure 1). Furthermore, patients heterozygous for
VEGF  -634CG also had a better 1-year survival rate
(adjusted HR, 2.08; 95% CI, 1.03–4.22; P = 0.042) than
those with the VEGF -634 GG genotype.
Further analyses combining the alleles, genotypes, and
haplotypes of the same gene did not substantiate the find-
ings from the single locus analysis (data not shown),
partly because of the low LD among the SNPs and the
small study size that did not allow for further stratification
analysis.
Discussion
The etiology of gastric cancer is multifactorial, multige-
netic and multistage [24,25]. It is known that during car-
cinogenesis, TGF- can switch from a tumor suppressor to
a tumor enhancer in the later stages of cancer [26]. With
dual role in cancer development, there is great interest in
analyzing the role of genetic variation in TGFB1 in cancer
progression and patient survival. For example, the TGFB1
-509C>T and rs1982073 (or rs1800470) polymorphisms
have been shown to be associated with breast cancer sur-
vival in a Chinese population [27-30] and chemoradio-
therapy response in 175 Finnish patients with head and
neck squamous cancer[31], respectively. However, neither
TGFB1 +869T>C nor +915G>C polymorphisms showed
any association with tumor relapse and progression in
bladder tumors without muscular invasive in a Spanish
population [32]. While a Korean study showed that the
variant T genotypes of the TGFB1 -509C>T SNP were asso-
ciated with a reduced risk of lung cancer [33], a Chinese
study of 414 patients and 414 controls [34] reported that
the genotypes were not associated with an overall risk of
developing gastric cancer but with a decreased risk of risk
of stage I or II gastric cancer. However, no survival analy-
ses were presented in these studies.
As noted, we did not find any statistical evidence to sup-
port a significant association between
TGFB1polymorphisms and overall survival in gastric can-
cer. However, the significant association between
TGFB1+915 CG/CC genotypes and 2-year survival for all
gastric cancer patients suggests that this TGFB1variant
may have attenuated the role of TGF-1 as a tumor sup-
pressor in the earlier stage of tumor progression. It is also
known that TGF-1 can switch from a tumor suppressor
to a tumor enhancer in the late stage of cancer [26]. Once
the tumors had grown bigger and become metastatic, the
resultant increase in somatic mutations or gains in the
copies of oncogenes may have outweighed the role of the
suppressor variants in the late stages of the tumor, leading
to no difference in overall survival of the patients with dif-
ferent genotypes of the TGFB1+915 G>C SNP. However,
this speculation needs to be validated in more rigorously
designed studies with a much larger sample size and more
information on the mutation spectrum in the tumors.
VEGF, as a key mediator of angiogenesis, also plays an
important role in the development of cancers. VEGF pol-
ymorphisms have also been shown to be associated with
survival in both gastric cancer and colorectal cancer
[35,36]. However, the results from published studies
remain inconsistent rather than conclusive. In a Greek
gastric cancer study of five VEGF  SNPs (-2578C>A, -
1154G>A, -634G>C, -460T>C, and +936C>T) in 312
patients [36], VEGF -2578 AA, -634 CC and +936TT gen-
otypes were associated with a significantly lower HR (bet-
Cumulative survival functions of the genotypes TGFB1 +915  G>C (rs1800471) and VEGF -634G>C (rs2010963) Figure 1
Cumulative survival functions of the genotypes 
TGFB1 +915 G>C (rs1800471) and VEGF -634G>C 
(rs2010963).Journal of Experimental & Clinical Cancer Research 2009, 28:94 http://www.jeccr.com/content/28/1/94
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ter survival) for 6-year survival of colorectal cancers.
Interestingly, another early Greek study of 100 gastric can-
cer patients suggested that only the VEGF  -634CC/CG
genotypes were associated with a decreased (poorer sur-
vival) 10-year survival, compared with the GG genotype
[35]. Our data on 167 gastric cancer patients indicated
that VEGF -634CC/CG carriers indeed had a poor 1-year
survival than those with the VEGF  -634 GG genotype.
Amano et al. [37] also reported that no significant associ-
ation was observed between the frequencies of the VEGF -
460T>C, +405G>C, and 936C>T genotypes and 3-year
disease-free survival of endometrial carcinoma patients in
a Japanese study of 105 endometrial carcinoma patients.
Because all these studies, including ours, have been rela-
tively small, there was limited ability to perform the more
powerful haplotype-based analysis that the analysis of a
single allele or locus effect [34].
This is the first report, to our knowledge, involving TGFB1
and VEGF polymorphisms and survival in gastric cancer
patients mainly consisting of a Caucasian population;
however, there were some limitations to the present study.
Although we tried to collect recurrence data on these
patients, we could not investigate this end-point due to
the lack of a pre-defined follow-up plan. A second limita-
tion was the fact that we only included three common
TGFB1  SNPs and three VEGF  SNPs. It is possible that
some other important SNPs were missed or that the
observed associations may be due to other polymor-
phisms in LD with the SNPs we studied. Also, no data on
serum/plasma protein levels were available for the geno-
type-phenotype correlation analysis, because only DNA
samples were available from these patients. There are
other genes in addition to TGFB1 and VEGF that also play
a role in cell growth and angiogenesis, representing a
complex interplay of many activating and inhibitory fac-
tors [38]. Furthermore, Helicobacter pylori infection, the
presence or absence of which was not reported in the
present study, is considered to be the cause of a progres-
sive accumulation of genotypic changes in gastric cancer,
which may lead to sporadic gastric cancer carcinogenesis
[39]. Finally, the study size was too small to have a suffi-
cient power to detect small HRs. For example, our post-
power calculation suggested that the sample size for an
equal number (n = 55) of subjects in each genotype of
each SNP, the power to detect an HR of 2 was <0.4, but
>0.8 for a HR of 3.4 for a follow-up time of 5 years. There-
fore, only the finding of HRs for 2-year survival of TGFB1
+915G>C would have a sufficient power, suggesting a
much larger study would be needed to effectively test our
hypothesis for effects of the overall survival.
Conclusion
In summary, we found that some polymorphisms TGFB1
and VEGF may be associated with 1- or 2-year survival
rates of gastric cancer patients. However, the present study
is small, and various genetic and epigenetic events may
also have led to an association between TGFB1 and VEGF
polymorphisms and gastric cancer prognosis and survival.
Therefore, larger and better-designed studies are required
to overcome the limitations in the present study (particu-
larly the information about Helicobacter pylori infection)
and further confirm our observations.
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